60770-51-6

Usage

Uses

Used in Pharmaceutical Industry:
5-Iodo-3(2H)-benzofuranone is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications. Its unique structure allows for the creation of molecules with enhanced biological activity and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Iodo-3(2H)-benzofuranone is utilized as a precursor in the production of agrochemicals, specifically for the development of new pesticides and herbicides. Its chemical properties make it a valuable component in the design of effective and targeted agrochemicals.
Used in Drug Discovery:
5-Iodo-3(2H)-benzofuranone is employed as a starting material in drug discovery processes, where its potential biological activities are explored and harnessed to create novel therapeutic agents. Its presence in synthesized compounds can influence their pharmacological properties, making it a useful tool in medicinal chemistry.
Used in Antimicrobial Agents:
5-Iodo-3(2H)-benzofuranone is used as an antimicrobial agent due to its inherent antibacterial, antifungal, and antiviral properties. It can be incorporated into formulations for treating infections and diseases caused by various microorganisms, contributing to the development of new antimicrobial therapies.
Used in Research and Development:
In the field of research and development, 5-Iodo-3(2H)-benzofuranone serves as a valuable compound for studying its potential role in various biological processes and disease mechanisms. Its unique structure and properties make it an interesting subject for scientific investigation, potentially leading to new insights and applications in medicine and chemistry.

InChI:InChI=1/C8H5IO2/c9-5-1-2-8-6(3-5)7(10)4-11-8/h1-3H,4H2

Upstream product

• 696-62-8 para-iodoanisole 
• 79-04-9 chloroacetyl chloride 
• 60770-38-9 3-acetoxy-5-iodo-benzofuran 
• 4068-75-1 methyl 5-iodosalicylate 
• 705262-57-3 2-((ethoxycarbonyl)methoxy)-5-iodobenzoic acid methyl ester 

Downstream Products

• 1032165-56-2 (Z)-2-(4-hydroxybenzylidene)-5-iodobenzofuran-3(2H)-one 
• 1316339-24-8 C₁₇H₁₅NO₃S 
• 1032165-57-3 (Z)-2-(4-(2-hydroxyethoxy)benzylidene)-5-iodobenzofuran-3(2H)-one 

Relevant academic research and scientific papers

Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis

Death-associated protein kinase-related apoptosis-inducing kinase-2 (DRAK2) is a serine/threonine kinase that plays a key role in a wide variety of cell death signaling pathways. Inhibition of DRAK2 was found to efficiently protect islet β-cells from apoptosis and hence DRAK2 inhibitors represent a promising therapeutic strategy for the treatment of diabetes. Only very few chemical entities targeting DRAK2 are currently known. We carried out a high throughput screening and identified compound 4 as a moderate DRAK2 inhibitor with an IC50value of 3.15?μM. Subsequent SAR studies of hit compound 4 led to the development of novel benzofuran-3(2H)-one series of DRAK2 inhibitors with improved potency and favorable selectivity profiles against 26 selected kinases. Importantly, most potent compounds 40 (IC50?=?0.33?μM) and 41 (IC50?=?0.25?μM) were found to protect islet β-cells from apoptosis in dose-dependent manners. These data support the notion that small molecule inhibitors of DRAK2 represents a promising strategy for the treatment of diabetes.

Novel brain penetrant benzofuropiperidine 5-HT6 receptor antagonists

7-Arylsulfonyl substituted benzofuropiperidine was discovered as a novel scaffold for 5HT6 receptor antagonists. Optimization by substitution at C-1 position led to identification of selective, orally bioavailable, brain penetrant antagonists with reduced hERG liability. An advanced analog tested in rat social recognition model showed significant activity suggesting potential utility in the enhancement of short-term memory.

AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS

The present invention provides a composition for diagnosing amyloid-related diseases, comprising a compound represented by general formula (I): wherein X represents O or the like; R1, R3, R4, R5, R6,

Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3(2 H)-benzofuranone derivatives

A new series of (Z)-2-(1-methyl-5-nitroimidazole-2-ylmethylene)-3(2 H)-benzofuranones (11a-p) and (Z)-2-(1-methyl-4-nitroimidazole-5-ylmethylene)-3(2 H)-benzofuranones (12a-m) were synthesized and assayed for their antibacterial activity against Gram-positive and Gram-negative bacteria. Most of the 5-nitroimidazole analogues (11a-p) showed a remarkable inhibition of a wide spectrum of Gram-positive bacteria (Staphylococcus aureus, Streptococcus epidermidis, MRSA, and Bacillus subtilis) and Gram-negative Klebsiella pneumoniae, whereas 4-nitroimidazole analogues (12a-m) were not effective against selected bacteria. The quantitative structure-activity relationship investigations were applied to find out the correlation between the experimentally evaluated activities with various parameters of the compounds studied. The QSAR models built in this work had reasonable predictive power and could be explained by the observed trends in activities.